Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of XTL Biopharmaceuticals Ltd.
No Price
Closing Price XTAE 01.05.2026:
3,10 ILA
01.05.2026 10:44
Current Prices from XTL Biopharmaceuticals Ltd.
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
TASE
XTLB.TA
ILA
01.05.2026 10:44
3,10 ILA
0,70 ILA
+29,17 %
Share Float & Liquidity
Free Float63,06 %
Shares Float596,75 M
Shares Outstanding946,24 M
Company Profile for XTL Biopharmaceuticals Ltd. Share
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
